No cosmetic product may be placed on the European Union market without a Cosmetic Product Safety Report (CPSR). This requirement, established by EU Cosmetics Regulation 1223/2009, forms the centrepiece of the Product Information File (PIF) — the complete regulatory dossier that the Responsible Person must compile and maintain for every cosmetic product. The CPSR is not a formality. It is the document that demonstrates, through structured scientific evidence, that a product is safe for human health under normal or reasonably foreseeable conditions of use.
What the Product Information File Must Contain
The PIF is the umbrella document under which the CPSR sits. As defined in Article 11 of Regulation 1223/2009, the PIF must include: a description of the cosmetic product, the CPSR itself, a description of the method of manufacturing and a statement of conformity with Good Manufacturing Practice (GMP), evidence of the claimed effects, and data on animal testing where applicable. The PIF must be kept at the address of the Responsible Person and made available to competent authorities on request.
Within this structure, the CPSR is by far the most technically demanding component. It is divided into two distinct parts, each with specific requirements.
Part A: Cosmetic Product Safety Information
Part A of the CPSR compiles the raw data and technical information needed to assess the safety of the product. It must include the following elements:
- Quantitative and qualitative composition: The full formula, listing every ingredient by its INCI (International Nomenclature of Cosmetic Ingredients) name, CAS number, and concentration in the final product. This includes the decomposition of multi-component raw materials into their individual constituents.
- Physical and chemical characteristics: Data on the product's appearance, pH, viscosity, stability, and other relevant physicochemical parameters.
- Microbiological quality: Specifications for the microbiological purity of the product, including challenge test results that demonstrate the efficacy of the preservative system. This is critical for aqueous formulas and products used near the eyes or on mucous membranes.
- Impurities and traces: Information on impurities in raw materials, residues from the manufacturing process, and traces of prohibited or restricted substances — with evidence that they are technically unavoidable and that the product remains safe.
- Packaging information: Data on the packaging material, including migration studies where relevant, and the interaction between the product and its container.
- Normal and reasonably foreseeable use: A description of how the product is intended to be used, including frequency, duration, application area, and target population (adults, children, specific skin types).
- Exposure assessment: Calculation of the consumer's exposure to the product and to each individual ingredient, considering the intended use conditions. This feeds directly into the Margin of Safety (MOS) calculation.
- Toxicological profiles of ingredients: Toxicological data for each ingredient, covering systemic toxicity, irritation, sensitisation, mutagenicity, carcinogenicity, and reproductive toxicity. For well-characterized ingredients, this may reference published safety assessments by the Scientific Committee on Consumer Safety (SCCS).
- Undesirable effects: Any known undesirable effects associated with the product or its ingredients, including data from post-market surveillance and cosmetovigilance reports.
Part B: Cosmetic Product Safety Assessment
Part B is the safety assessor's evaluation. It must be carried out by a qualified person holding a diploma or degree in pharmacy, toxicology, medicine, or a related discipline, as defined by Article 10(2) of the Regulation. The safety assessor reviews all information compiled in Part A and provides a reasoned conclusion on the safety of the product.
The assessment must address whether the product is safe under its intended and foreseeable use conditions. The MOS calculation is central to this assessment — for each ingredient with a systemic exposure pathway, the assessor calculates the ratio between the no-observed-adverse-effect level (NOAEL) and the estimated systemic exposure dose (SED). A MOS of 100 or above is generally considered acceptable, providing a safety margin that accounts for inter-species and inter-individual variability.
Stability Data and Shelf Life
Stability testing data feeds directly into the CPSR. The product's physical, chemical, and microbiological stability must be demonstrated under defined storage conditions over the intended shelf life. Accelerated stability studies and real-time data support the safety assessor's conclusion that the product remains safe throughout its period of use. Products with a shelf life exceeding 30 months must display a Period After Opening (PAO) symbol; those with a shorter shelf life must display a "best before" date.
Why Manual Dossier Assembly Is a Risk
The CPSR demands that data from multiple sources — raw material specifications, toxicological profiles, MOS calculations, stability results, microbiological data, packaging studies — converge into a single, internally consistent document. In many cosmetics companies, this data lives in disconnected systems: raw material data in supplier files, formulations in spreadsheets, stability data in laboratory notebooks, and MOS calculations in standalone tools. Assembling a CPSR from these disparate sources is slow, error-prone, and difficult to audit. When a formula changes — even a minor adjustment to a preservative concentration — the entire dossier must be checked for consistency.
How Purpose-Built Software Generates the CPSR
In a vertically integrated formulation platform like Labify® Beauté, the data needed for a CPSR is not scattered across systems — it is the same data the R&D team uses daily. The formula composition, the raw material profiles (including INCI names, CAS numbers, and toxicological data from a database of 100,000+ raw materials), the MOS calculations, the stability study results, and the microbiological specifications all live in the same connected platform.
Dossier generation in Labify® Beauté works from templates that map directly to the structure required by Annex I of Regulation 1223/2009. The platform populates each section of the CPSR automatically: Part A draws from the live formula data, exposure calculations, and raw material documentation; Part B provides the structured inputs the safety assessor needs to complete their evaluation. When a formula is modified, the dossier updates reflect the change immediately — no manual reconciliation, no risk of version mismatch between the formula in production and the formula described in the regulatory file.
Audit Readiness and Regulatory Inspections
Because every data point in the generated CPSR is traceable to its source within the platform — a specific raw material record, a specific formula version, a specific stability study — the resulting dossier is inherently audit-ready. Regulatory inspectors reviewing the PIF can follow each claim back to its origin. This traceability is not just a convenience; it is what the regulation expects, and it is what distinguishes a defensible CPSR from one assembled under time pressure from fragmentary records.
For cosmetics companies operating across multiple markets and managing portfolios of dozens or hundreds of products, the ability to generate and maintain CPSRs from a single source of truth is not optional — it is the difference between regulatory confidence and regulatory exposure.